Reduced tumour necrosis factor receptor superfamily 13C inversely correlated with tumour necrosis factor superfamily 13B in patients with immune thrombocytopenia
Authors:
Open Access
- 30 May 2014
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 166 (5) , 783-791
Abstract
To investigate the expression of tumour necrosis factor superfamily 13B (TNFSF13B) receptors in immune thrombocytopenia (ITP) and their correlation with disease activity, we investigated the protein and mRNA levels of TNFSF13B, tumour necrosis factor receptor superfamily 13C (TNFRSF13C), TNFRSF13B and TNFRSF17 by flow cytometry, enzyme‐linked immunosorbent assay and real time quantitative polymerase chain reaction. All CD19+B lymphocytes expressed TNFRSF13C by flow cytometry, but the mean fluorescence intensity (MFI) was decreased in patients with active disease compared to patients in remission and healthy controls, while no significant difference of TNFRSF13C mRNA was found between ITP patients and controls. The mRNA and plasma TNFSF13B were elevated in active ITP patients, and TNFRSF13C MFI level was inversely correlated with plasma TNFSF13B in active patients. In vitro assays showed that TNFRSF13C MFI was decreased after long exposure to TNFSF13B. No significant difference for TNFRSF13B or TNFRSF17 was found between ITP patients and controls. In conclusion, TNFRSF13C expression is reduced on CD19+ cells in active ITP patients. This down‐regulation occurs through a post‐transcriptional mechanism and could be a consequence of chronic increase of TNFSF13B.Keywords
Funding Information
- National Natural Science Foundation of China (81100335,81070396,81100334,81100336,81100348,81101869,81170475,81200344,81202307, 81270578, 81300383)
- National Natural Science Foundation of China (81370623,81370616,81300384)
- National Basic Research Program of China (973 Program, No. 2009CB521904, No. 2011CB503906)
- National High Technology Research and Development Program of China (863 Program, No. 2012AA02A505))
- National Natural Science Funds for Distinguished Young Scholar (81125002)
- National Public Health Grand Research Foundation (201202017)
- Outstanding Young Scientist Research Award Foundation of Shandong Province (No. 2008BS03025, No. BS2010YY024, No. BS2010YY039, No. BS2011SW013, No. BS2011YY021)
- State Key Clinical Specialty of China for Blood Disorders, the Research Fund for the Doctoral Program of Higher Education of China (20100131120058)
- State Program of National Natural Science Foundation of China for Innovative Research Group (81321061)
This publication has 59 references indexed in Scilit:
- Thrombopoietin-receptor agonistsCurrent Opinion in Hematology, 2012
- Novel evidence‐based systemic lupus erythematosus responder indexArthritis Care & Research, 2009
- High‐level serum B‐cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpuraBritish Journal of Haematology, 2006
- Expression and occupancy of BAFF‐R on B cells in systemic lupus erythematosusArthritis & Rheumatism, 2005
- Management of Adult Idiopathic Thrombocytopenic PurpuraAnnual Review of Medicine, 2005
- BAFF selectively enhances the survival of plasmablasts generated from human memory B cellsJournal of Clinical Investigation, 2003
- BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cellsNature Immunology, 2002
- Immune Thrombocytopenic PurpuraNew England Journal of Medicine, 2002
- Baff Mediates Survival of Peripheral Immature B LymphocytesJournal of Experimental Medicine, 2000
- NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor SuperfamilyScience, 1997